Mersana Therapeutics, Inc. financial data

Symbol
MRSN on Nasdaq
Location
840 Memorial Drive, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 172 % -41.9%
Debt-to-equity -364 % -139%
Return On Equity 183 %
Return On Assets -69.3 % -79.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5M shares -96%
Common Stock, Shares, Outstanding 5M shares -95.9%
Entity Public Float 226M USD -37.8%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 4.99M shares +1.71%
Weighted Average Number of Shares Outstanding, Diluted 4.99M shares +1.71%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 33.2M USD -4.76%
Research and Development Expense 69M USD -4.43%
General and Administrative Expense 31.5M USD -25%
Nonoperating Income (Expense) 1.43M USD -75.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.55M USD +31.9%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -70.1M USD +6.08%
Earnings Per Share, Basic 0 USD/shares +35.5%
Earnings Per Share, Diluted 0 USD/shares +35.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.4M USD -28.5%
Cash, Cash Equivalents, and Short-term Investments 135M USD
Accounts Receivable, after Allowance for Credit Loss, Current 168K USD -83.2%
Assets, Current 60M USD -62.6%
Property, Plant and Equipment, Net 163K USD -92.6%
Operating Lease, Right-of-Use Asset 2.04M USD -62.3%
Other Assets, Noncurrent 500K USD -48.9%
Assets 62.7M USD -63%
Accounts Payable, Current 2.39M USD +17.7%
Employee-related Liabilities, Current 3.89M USD -61.9%
Accrued Liabilities, Current 14.8M USD -20.5%
Contract with Customer, Liability, Current 23.8M USD -24.2%
Liabilities, Current 43.3M USD -36.7%
Contract with Customer, Liability, Noncurrent 79M USD -5.86%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 122M USD -27.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -952M USD -7.95%
Stockholders' Equity Attributable to Parent -59.5M USD -5776%
Liabilities and Equity 62.7M USD -63%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.3M USD +10.2%
Net Cash Provided by (Used in) Financing Activities -3.14M USD -154%
Net Cash Provided by (Used in) Investing Activities 27M USD
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 5M shares -95.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.46M USD +94.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.9M USD -28.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 704K USD -19.2%
Deferred Tax Assets, Valuation Allowance 263M USD +9.76%
Deferred Tax Assets, Gross 264M USD +9.33%
Operating Lease, Liability 5.15M USD -38.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -70.1M USD +6.02%
Lessee, Operating Lease, Liability, to be Paid 5.5M USD -42%
Operating Lease, Liability, Current 2.29M USD -38.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.31M USD -68.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.19M USD +5.33%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 349K USD -67.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.31M USD -68.7%
Deferred Tax Assets, Operating Loss Carryforwards 122M USD -3.78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 316K USD -25.3%
Deferred Tax Assets, Net of Valuation Allowance 1.25M USD -39.8%
Share-based Payment Arrangement, Expense 9.26M USD -46.1%
Interest Expense 4.09M USD +14.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%